Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 212-782-2 | CAS number: 868-77-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Health surveillance data
Administrative data
- Endpoint:
- health surveillance data
- Type of information:
- other: human patch test data collection consecutive patients
- Adequacy of study:
- other information
- Study period:
- 21 February 2005 to 30 June 2007 Malmö
1 July 2005 to 30 June 2007 Singapore - Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
- Remarks:
- Bias-positive: patients of dermatologists or dermal clinics are a cohort preselected for having a problem with the skin, so that no valid assessment of actual prevalence can be done.
Data source
Reference
- Reference Type:
- publication
- Title:
- Screening for acrylate/methacrylate allergy in the beseline series: our experience in Sweden and Singapore
- Author:
- Goon A T-J et al
- Year:
- 2 008
- Bibliographic source:
- Contact dermatitis 2008, 59: 307-313
Materials and methods
- Study type:
- other: study specifically designed to determine the prevalence of contact allergy to acrylates/methacrylates in entire populations of patients patch tested in a dermatology centre
- Endpoint addressed:
- skin sensitisation
- Principles of method if other than guideline:
- The allergens were applied onto small (8 mm) Finn Chambers1 (Epitest Ltd Oy, Tuusula, Finland)
on Scanpor1 (Norgesplaster A/S, Vennesla, Norway). The tests were applied to the upper part
of the back and left for 2 D. Tests were read on D3 or D4 and D7 by a dermatologist, and the
reactions were scored according to International Contact Dermatitis Research Group criteria. - GLP compliance:
- not specified
Test material
- Reference substance name:
- 2-hydroxyethyl methacrylate
- EC Number:
- 212-782-2
- EC Name:
- 2-hydroxyethyl methacrylate
- Cas Number:
- 868-77-9
- Molecular formula:
- C6H10O3
- IUPAC Name:
- 2-hydroxyethyl methacrylate
Constituent 1
- Specific details on test material used for the study:
- 2% in petrolatum
Method
- Type of population:
- general
- occupational
- Ethical approval:
- not specified
- Details on study design:
- Study on all patients patch tested to the baseline patch test series in two dermatology centres – the
Department of Occupational and Environmental Dermatology,Malmo¨ University Hospital,Malmo¨ ,
Sweden and National Skin Centre, Singapore. Five acrylate/methacrylate allergens, obtained from
Chemotechnique Diagnostics (Vellinge, Sweden), were included in the baseline series of both
centres.
The acrylate/methacrylate allergens added to the baseline series were
2-hydroxyethyl methacrylate (2-HEMA) 2.0% petrolatum (pet.) w/w,
methyl methacrylate (MMA) 2.0% pet. w/w,
ethylene glycol dimethacrylate (EGDMA) 2% pet. w/w,
triethylene glycol diacrylate (TREGDA) 0.1% pet. w/w, and
2-hydroxypropyl acrylate (2-HPA) 0.1% pet. w/w.
The additional allergens including 2-HEMA were applied to all patients for whom the baseline series
had been ordered over virtually the same period of at least 2 years in both centres.
Results and discussion
- Results:
- Results of examinations
19/2790 (0.7%) of all patients tested reacted positive for HEMA.
19/38 (50%) patients tested positive for at least one acrylate/methacrylate tested positive for HEMA.
One patient who had negative readings to 2-HEMA on D3 and D7 was found to have a positive reaction to this allergen when she was seen again 1 month after the patch test application.
Any other information on results incl. tables
Overall, 38 patients in total had reacted to acrylate/ methacrylate allergens in the baseline series during the study period in both populations.
In Malmö, there were 26 (1.6%) of 1609 patients (mean age 46 years, range 23–81 years) with positive patch tests to acrylate/methacrylate allergens in the baseline series. There were 9 (1.4%) of 632 males (mean age 45 years, range 24–72 years) and 17 (1.7%) of 977 females (mean age 46 years, range 23–81 years) in this group.
Of the 26 positive reactors in Malmö, 14 (54%) had been found to have relevant (clinical) reactions to acrylate/methacrylate allergens; 6 female nail technicians, 3 female dental workers, 3 men who worked with ultraviolet-cured acrylates, and 2 female acrylic nail users.
In Singapore, there were 12 (1.0%) of 1181 patients (mean age 38 years, range 19–61 years) with positive patch tests to acrylate/methacrylate allergens in the baseline series. There were 5 (0.9%) of 547 males (mean age 38 years, range 19–56 years) and 7 (1.1%) of 634 females (mean age 38 years,range 23–61 years) in this group.
Applicant's summary and conclusion
- Executive summary:
Five acrylate/methacrylate allergens (2-hydroxyethyl methacrylate, methyl methacrylate, ethylene glycol dimethacrylate, triethylene glycol diacrylate, and 2-hydroxypropyl acrylate) were included in the baseline series for at least 2 years in Malmö and Singapore to determine the prevalence of acrylate/methacrylate allergy in all patients tested to the baseline patch test series.
38/2790 (1.36%) patients in total had reacted to acrylate/methacrylate allergens in the baseline series
during the study period in both populations.
19/38 (50%) patients tested positive for at least one acrylate/methacrylate tested positive for HEMA.
19/2790 (0.7%) of all patients tested reacted positive for HEMA.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.